Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 76

2.

Patient-reported pain and other quality of life domains as prognostic factors for survival in a phase III clinical trial of patients with advanced breast cancer.

Smyth EN, Shen W, Bowman L, Peterson P, John W, Melemed A, Liepa AM.

Health Qual Life Outcomes. 2016 Mar 25;14:52. doi: 10.1186/s12955-016-0449-z.

3.
4.

The clinical effectiveness and cost-effectiveness of gemcitabine for metastatic breast cancer: a systematic review and economic evaluation.

Takeda AL, Jones J, Loveman E, Tan SC, Clegg AJ.

Health Technol Assess. 2007 May;11(19):iii, ix-xi, 1-62. Review.

5.

Clinical interpretation of quality-of-life outcomes: an investigation of data from the randomized trial of gemcitabine plus paclitaxel compared with paclitaxel alone for advanced breast cancer.

Hopwood P, Watkins J, Ellis P, Smith I.

Breast J. 2008 May-Jun;14(3):228-35. doi: 10.1111/j.1524-4741.2008.00567.x. Epub 2008 Apr 21.

PMID:
18433403
6.

Gemcitabine for the treatment of metastatic breast cancer.

Jones J, Takeda A, Tan SC, Cooper K, Loveman E, Clegg A.

Health Technol Assess. 2009 Sep;13 Suppl 2:1-7. doi: 10.3310/hta13suppl2/01. Review.

7.

Gemcitabine plus Paclitaxel versus Paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment.

Albain KS, Nag SM, Calderillo-Ruiz G, Jordaan JP, Llombart AC, Pluzanska A, Rolski J, Melemed AS, Reyes-Vidal JM, Sekhon JS, Simms L, O'Shaughnessy J.

J Clin Oncol. 2008 Aug 20;26(24):3950-7. doi: 10.1200/JCO.2007.11.9362.

PMID:
18711184
8.

Randomised trial of paclitaxel versus doxorubicin as first-line chemotherapy for advanced breast cancer: quality of life evaluation using the EORTC QLQ-C30 and the Rotterdam symptom checklist.

Kramer JA, Curran D, Piccart M, de Haes JC, Bruning PF, Klijn JG, Bontenbal M, van Pottelsberghe C, Groenvold M, Paridaens R.

Eur J Cancer. 2000 Aug;36(12):1488-97.

PMID:
10930796
9.

Quality of life in phase II trials: a study of methodology and predictive value in patients with advanced breast cancer treated with paclitaxel plus granulocyte colony-stimulating factor.

Seidman AD, Portenoy R, Yao TJ, Lepore J, Mont EK, Kortmansky J, Onetto N, Ren L, Grechko J, Beltangady M, et al.

J Natl Cancer Inst. 1995 Sep 6;87(17):1316-22.

PMID:
7544834
10.
11.

A GINECO randomized phase II trial of two capecitabine and weekly paclitaxel schedules in metastatic breast cancer.

Lortholary A, Hardy-Bessard AC, Bachelot T, de Rauglaudre G, Alexandre J, Bourgeois H, Jaubert D, Paraiso D, Largillier R.

Breast Cancer Res Treat. 2012 Jan;131(1):127-35. doi: 10.1007/s10549-011-1776-8. Epub 2011 Sep 24.

PMID:
21947680
12.

Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer--a randomized trial with quality of life as the primary outcome. UK NSCLC Gemcitabine Group. Non-Small Cell Lung Cancer.

Anderson H, Hopwood P, Stephens RJ, Thatcher N, Cottier B, Nicholson M, Milroy R, Maughan TS, Falk SJ, Bond MG, Burt PA, Connolly CK, McIllmurray MB, Carmichael J.

Br J Cancer. 2000 Aug;83(4):447-53.

13.

An exploratory study of frequent pain measurement in a cancer clinical trial.

Ingham J, Seidman A, Yao TJ, Lepore J, Portenoy R.

Qual Life Res. 1996 Oct;5(5):503-7.

PMID:
8973130
14.

Gemcitabine, paclitaxel, and trastuzumab in metastatic breast cancer.

Sledge GW Jr.

Oncology (Williston Park). 2003 Dec;17(12 Suppl 14):33-5.

PMID:
14768403
15.

Health-related quality of life in early breast cancer.

Groenvold M.

Dan Med Bull. 2010 Sep;57(9):B4184.

PMID:
20816024
16.

Phase II study of gemcitabine plus paclitaxel in metastatic breast cancer patients with prior anthracycline exposure.

Demiray M, Kurt E, Evrensel T, Kanat O, Arslan M, Saraydaroglu O, Ercan I, Gonullu G, Gokgoz S, Topal U, Tolunay S, Tasdelen I, Manavoglu O.

Cancer Invest. 2005;23(5):386-91.

PMID:
16193637
17.

Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer.

Ranson M, Davidson N, Nicolson M, Falk S, Carmichael J, Lopez P, Anderson H, Gustafson N, Jeynes A, Gallant G, Washington T, Thatcher N.

J Natl Cancer Inst. 2000 Jul 5;92(13):1074-80.

PMID:
10880550
19.
20.

Topotecan, pegylated liposomal doxorubicin hydrochloride and paclitaxel for second-line or subsequent treatment of advanced ovarian cancer: a systematic review and economic evaluation.

Main C, Bojke L, Griffin S, Norman G, Barbieri M, Mather L, Stark D, Palmer S, Riemsma R.

Health Technol Assess. 2006 Mar;10(9):1-132. iii-iv. Review.

Supplemental Content

Support Center